Josh Hardman is the founder of Psychedelic Alpha, an independent newsletter, community and consultancy firm devoted to the psychedelics industry -- from business and drug development through to policy reform and culture. Using data-driven reporting, analysis and commentary, Hardman strives to empower individuals and organizations with the knowledge, network and nuance to make an impact within the emerging field of psychedelic medicine and beyond.

Having studied at the London School of Economics and University of California, Berkeley, Hardman spent several years working in economic policy, advising startups and following the early days of the so-called ‘psychedelic renaissance’ very closely. He has since authored hundreds of analyses on topics broadly related to psychedelic business, policy and research, such as commercialization, IP and regulation, and has also worked on both the investment and operator side of the industry.

Hardman has spoken about psychedelic drug development and industry at conferences including SXSW, Horizons, and SOCAP Global, and has acted as an expert witness at meetings held by bodies such as the European Parliament and the U.S. Department of Health and Human Services. He has also lectured on psychedelic drug development at institutions, such as the University of Wisconsin-Madison.

SXSW, Pharmaceutical, Medicine Startup, Consulting, Start-up Advisor, Science, Alternative Medicine, Neuroscience, Health, Natural Medicine,